Daiichi Sankyo Group's Position on Counterfeit Pharmaceutical Products

Daiichi Sankyo Group is committed to contributing to the enrichment of quality of life around the world through creating innovative pharmaceuticals that address diverse medical needs. Counterfeit or falsified pharmaceutical products represent a serious and growing risk to global public health and patient safety. These products—deliberately and fraudulently mislabeled with respect to content, source, or identity—may contain incorrect, insufficient, harmful, or no active ingredients, posing significant risks to patients and undermining trust in healthcare systems.

Our Position

In response to the escalating challenge of counterfeit pharmaceutical products, we are committed to a comprehensive and proactive approach to safeguarding the integrity of our products throughout the supply chain:

Enhancement of Packaging and Traceability

We are taking appropriate measures to protect the integrity of our products and enhance their traceability in accordance with the regulations of each country and region. These measures include security enhancements to packaging design, such as tamper-evident and anti-counterfeiting features, as well as traceability initiatives such as serialization and GS1 code labeling requirements on pharmaceutical packaging where appropriate. As a global pharmaceutical company, we will continue to strengthen anti-counterfeit measures and traceability of our products in accordance with the respective risks.

Collaboration and Industry Engagement

Recognizing that combating counterfeit pharmaceutical products demands concerted efforts, we collaborate closely with relevant stakeholders, including pharmaceutical industry associations and other pharmaceutical companies, regulatory authorities, healthcare professionals, law enforcement agencies, and the Pharmaceutical Security Institute (PSI)[1].

Commitment to Patient Safety

The safety and well-being of patients is at the heart of our anti-counterfeiting initiatives. Guided by our commitment to patients, we are dedicated to ensuring that patients receive authentic Daiichi Sankyo medicines that meet applicable quality, safety, and regulatory standards.

Our ongoing efforts aim to maintain and enhance the reliability of our products, helping to protect patients who use our medicines from the dangers posed by counterfeit pharmaceutical products.

Through these efforts, Daiichi Sankyo remains committed to maintaining robust product security and patient care, contributing to global initiatives that combat the proliferation of counterfeit pharmaceutical products.

[1] PSI is a trade organization that coordinates information sharing and investigations into counterfeit pharmaceutical products among member companies to share intelligence on pharmaceutical crimes affecting their products, collaborate on investigations of mutual interest and interact with law enforcement.